Lung Cancer

An Evidence-Based Approach to Multidisciplinary Management

1st Edition - August 24, 2023
Editors: Erin Alexis Gillaspie, Leora Horn, Amanda S. Cass
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 6 9 5 7 3 - 2
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 2 8 5 2 3 - 3
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 6 9 5 7 4 - 9

Care of the lung cancer patient—screening, diagnosis, and treatment—has undergone recent dramatic changes due to technologic and research-driven advances. Lung Cancer: An… Read more

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Care of the lung cancer patient—screening, diagnosis, and treatment—has undergone recent dramatic changes due to technologic and research-driven advances. Lung Cancer: An Evidence-Based Approach to Multidisciplinary Management covers every aspect of this fast-changing field, including new screening guidelines, new practice standards, and new treatment advances that have led to higher survival rates. This practical, clinically oriented resource provides thorough, evidence-based coverage from experts in the field, including the increasingly important precision medicine approach in lung cancer planning and management.

Cover image
Title page
Table of Contents
Copyright
Dedication
Preface
List of Contributors
List of Illustrations
List of Tables
1. Lung cancer screening and prevention
Epidemiology, risk factors, and prevention of lung cancer
History and evolution of lung cancer screening
Pros and cons of lung cancer screening
Current screening eligibility guidelines and recommendations
Cost effectiveness of lung cancer screening
Implementation of lung cancer screening
Current status of lung cancer screening
Future directions of lung cancer screening
References
2. Lung cancer: Diagnostic techniques
Introduction
Approach to diagnosis and staging of lung cancer
Staging of lung cancer: Noninvasive methods
Diagnosis and staging of lung cancer
Bronchoscopic techniques for lung biopsy
Novel techniques for diagnosis of lung nodules
Cone-beam computed tomography
Image-guided percutaneous diagnosis
Pleural-based procedures
New and emerging strategies for diagnosis and risk stratification
Conclusion
References
3. Histology and molecular testing
Introduction
Pulmonary adenocarcinoma
Clinical and prognostic relevance of adenocarcinoma subtypes
Squamous cell carcinoma
Neuroendocrine carcinomas
Other pulmonary carcinomas
Pathological staging of lung carcinoma—AJCC 8th edition
Predictive biomarker and molecular testing
Testing algorithm
Testing methods and assays
Selecting samples for testing
Lung cancer patients requiring biomarker testing
Timing of biomarker testing
Future perspective
References
4. Surgical considerations in lung cancer treatment
Introduction
Operative procedures
Approach to treatment selection
Conclusions
References
5. Surgically resectable disease
Introduction
Clinical stages I and II
Clinical stage III
Special surgical considerations
Conclusion
References
6. Oligometastatic disease
Introduction
Treatment
Prognostic factors
Future directions
Suggested Reading 
References
7. Locally advanced non–small cell lung cancer
Introduction
Treatment of patients with potentially resectable disease
Radiation therapy considerations for unresectable disease
Chemotherapy considerations for unresectable disease
Targeted therapies in locally advanced NSCLC
Immunotherapy in locally advanced NSCLC
Conclusions
References
8. First-line therapy
Anti-PD-1/PD-L1 monotherapy as first-line therapy in patients with advanced non–small cell lung cancer without oncogenic drivers (EGFR, ALK wild type)
Anti-PD-1/PD-L1 combinations with chemotherapy as first-line treatment in patients with advanced NSCLC
Checkpoint inhibitor combinations
Additional considerations
Selecting the optimal chemotherapy regimen
Conclusion
References
9. Second-line therapy in advanced non–small cell lung cancer
Introduction
Cytotoxic chemotherapy
Immunotherapy
Biomarkers of immune checkpoint inhibitor benefit
Management of disease progression after front-line immunotherapy
Ongoing clinical trials
Conclusions
References
10. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach
Introduction and epidemiology
Molecular pathways and mutations
Molecular testing at diagnosis
Overview of generation of EGFR tyrosine kinase inhibitors
Current treatment paradigm
EGFR tyrosine kinase inhibitors and resistance mechanisms
Current therapeutic challenges and considerations
Conclusions and future directions
References
11. Diagnosis a nd treatment of anaplastic lymphoma kinase (ALK) rearranged non−small cell lung cancer
Introduction
Diagnosis
Staging
First-line treatment for metastatic disease
Central nervous system disease
Disease progression
Clinical management
Future directions
Conclusions
References
12. Other molecular cohorts including ROS1, BRAF, HER2, MET, NT RK, RET, KRAS
Introduction
ROS-1
BRAF
MET
RET
HER-2
NTRK
KRAS
Conclusions
References
13. Immunotherapy
Single-agent immunotherapy
Combination IO/IO or Chemotherapy/IO
Assessment of response
Safety and toxicity management
References
14. Small cell lung cancer
Introduction
Clinical presentation and classification
Therapeutic management of small cell lung cancer
Conclusion
References
Index